Sandoz launches generic mental disorder treatment

Alaric DeArment

1/21/2010

PRINCETON, N.J. Sandoz has launched a generic version of a drug for schizophrenia and bipolar disorder, the generic drug maker announced.

Sandoz, the generics arm of Swiss pharmaceutical giant Novartis, introduced risperidone orally disintegrating tablets in the 2-mg, 3-mg and 4-mg strengths.

The drug is a generic version of Johnson & Johnson’s Risperdal M-TAB, which had sales of $108 million in 2008, according to IMS Health.

Walgreens buyout reportedly could result in three divisions

Walgreens’ three core segments—U.S. pharmacy retailer Walgreens, U.K.-based Boots and specialty unit Shields Health Solutions—could become three independent divisions, per a report.

Ulta Beauty sets date for experiential beauty event

Ulta Beauty World will take place on April 26 in San Antonio, Texas.

CVS Health to open smaller format stores

Each location will average less than 5,000 square feet and will feature a full-service pharmacy with limited over-the-counter products available for purchase.

Walgreens reportedly close to roughly $10B deal to go private

The deal could be finalized by Thursday, per a WSJ report.

Sycamore Partners reportedly working on financing to acquire Walgreens

A potential buyout reportedly would include terms loans, a bridge loan and asset-based lending.